T1	Intervention 398 695	We treated patients with coronary artery disease with sulfasalazine, an inhibitor of NFÎºB, and placebo in a randomized, double-blind, crossover study design. Brachial artery flow-mediated dilation (FMD) and digital vascular function were measured at baseline and after each 6-week treatment period
